☆ 4.6 Article

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Urology & Nephrology

Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors

Naba Farooqui et al.

Summary: This study found that immune checkpoint inhibitors (ICIs) therapy may lead to acute kidney injury (AKI) and there are no biomarkers currently available to distinguish AKI caused by ICIs from other causes. The urine levels of cytokines such as TNF-a, IL-2, and IL-10 were significantly higher in AKI-ICI patients. Therefore, these T-cell responses and their respective cytokines may be helpful in differentiating AKI-ICI from AKI-other.

KIDNEY INTERNATIONAL REPORTS (2023)

添加到收藏夹

Article Oncology

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity

Yared Hailemichael et al.

Summary: Immune checkpoint blockade therapy can cause immune-related adverse events. IL-6 expression is higher in colitis and Th17 cells are more prevalent in immune-related enterocolitis. Anti-CTLA-4 induces stronger Th17 memory in colitis than anti-PD-1. In mouse models, IL-6 blockade enhances tumor control and increases CD4(+)/CD8(+) effector T cell density, while reducing Th17, macrophages, and myeloid cells. Combined IL-6 blockade and ICB enhances tumor rejection and mitigates EAE symptoms. IL-6 blockade with ICB can decouple autoimmunity from antitumor immunity.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy

Megan L. Baker et al.

Summary: In patients receiving ICI therapy, AKI is common and associated with higher mortality, however, AKI related to AIN is associated with lower mortality.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Cell Biology

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era

Laura Kalfeist et al.

Summary: Glucocorticoids are widely prescribed drugs in cancer patients due to their anti-inflammatory, anti-oedema, and anti-allergy properties. They are used in various clinical situations in oncology, including managing cancer-related symptoms and preventing or treating side effects or immune-related adverse events of anti-cancer therapies. Moreover, glucocorticoids have been found to affect immune response and tumor efficacy.

CELLS (2022)

添加到收藏夹

Article Oncology

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort et al.

Summary: TNF blockers can help manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma, and may enhance the efficacy of immune checkpoint inhibitors. The combination of certolizumab showed a high response rate in patients, warranting further investigation. Both combinations were found to be safe and showed clinical and biological activities in human patients.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Rheumatology

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors

Jeffrey Aldrich et al.

Summary: The study found that ICI-myositis is rare but severe in cancer patients receiving immune checkpoint inhibitors, with over half of the patients presenting with overlap manifestations leading to worse outcomes, including respiratory failure and death. None of the patients with ICI-myositis alone died as a result of adverse events. Optimal treatment strategies remain to be determined.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Fangwen Zou et al.

Summary: Treatment with vedolizumab compared with infliximab for IMDC led to comparable IMDC response rates, shorter duration of steroid use, fewer hospitalizations, and lower IMDC recurrence, though with slightly longer time to IMDC response. Higher number of SIT doses was associated with better survival outcome, while more steroid exposure resulted in worse patient outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Daniel Araujo et al.

Summary: This study evaluated the efficacy and hepatotoxicity of infliximab in patients with steroid-refractory immune-related adverse events (irAEs). The results showed that infliximab was effective in resolving irAEs without inducing hepatotoxicity in this dose-limited setting.

CURRENT ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis

Maen Abdelrahim et al.

Summary: This study presents a 10-year experience at MD Anderson Cancer Center of patients diagnosed with melanoma and treated with immune checkpoint inhibitors, evaluating the incidence of acute kidney injury (AKI), associated factors, and its association with overall survival. The incidence of AKI following ICI use was found to be infrequent and not associated with mortality, with factors such as age, race, and medication use influencing the risk of AKI.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report

Shohei Moriyama et al.

Summary: Immune checkpoint inhibitors can lead to cardiac immune-related adverse events, such as pericarditis. In this case, a patient developed irAE pericarditis after treatment with nivolumab, which was successfully managed with a combination of corticosteroids and infliximab, while maintaining a favorable response to cancer treatment.

EUROPEAN HEART JOURNAL-CASE REPORTS (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study

Yukio Kadokawa et al.

Summary: This study investigated the outcomes of IFX treatment among 8 Japanese patients with various types of cancer, showing that some patients responded to IFX. However, potential CMV and CD infections should be recognized as concerns for patients receiving IFX treatment.

MOLECULAR AND CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis

Jamie S. Lin et al.

Summary: Infliximab may be a treatment option for achieving durable and complete renal recovery in patients with CPI-ATIN, representing a potential steroid-sparing strategy in challenging cases. Rigorous clinical studies are needed to evaluate the risk-benefit analysis for infliximab usage in CPI-ATIN patients.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Rheumatology

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Tawnie J. Braaten et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Oncology

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry

Rik J. Verheijden et al.

CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Review Oncology

Review: The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs)

Wanhai Ke et al.

THORACIC CANCER (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Severe steroid refractory gastritis induced by Nivolumab: A case report

Helene Hjorth Vindum et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Article Otorhinolaryngology

Recurrent audiovestibular dysfunction and associated neurologicalimmune-relatedadverse events in a melanoma patient treated with nivolumab and ipilimumab

Jonathan S. Choi et al.

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)

添加到收藏夹

Article Medicine, General & Internal

Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab

Koki Nakashima et al.

INTERNAL MEDICINE (2020)

添加到收藏夹

Article Oncology

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

Jennifer Cautela et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome

Daniel Giglio et al.

CASE REPORTS IN ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma

Maria Paparoupa et al.

CASE REPORTS IN GASTROENTEROLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Elisabeth Perez-Ruiz et al.

NATURE (2019)

添加到收藏夹

Article Oncology

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey

Candice Lesage et al.

JOURNAL OF IMMUNOTHERAPY (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Yousef R. Badran et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Review Oncology

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

Houssein Safa et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

New therapeutic perspectives to manage refractory immune checkpoint-related toxicities

Filipe Martins et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Victoria A. Chang et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Daniel H. Johnson et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Multidisciplinary Sciences

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

Florie Bertrand et al.

NATURE COMMUNICATIONS (2017)

添加到收藏夹

Article Oncology

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Morganna Freeman-Keller et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Blocking Tumor Necrosis Factor a Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma

Florie Bertrand et al.

CANCER RESEARCH (2015)

添加到收藏夹

Article Immunology

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

K Takeda et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.